Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing

Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma

“…Several reports have suggested that the SIB plans are superior to planning the boost separately. 15,16 In general, however, plans generated in these reports have relied on the initial optimization parameters established in dosimetric exercises. Our experience suggests that a concomitant boost schedule delivered via a sequential set of plans can meet the established set of constraints as well as SIB, if sufficient time is invested in individual plan optimization.…”

A Phase I/II Study of Altered Fractionated IMRT Alone for Intermediate T-Stage Oropharyngeal Carcinoma

“…Second, the selection of what dose per fraction to use may not be straightforward. Simultaneous integrated boost IMRT (SIB-IMRT) plans, which are usually preferred over IMRT plans with sequential field reductions due to ease of treatment planning and more conformal dose distributions [17,33], deliver different doses per fraction to each of the target volumes over the same total number of fractions. When using once-a-day SIB-IMRT schedules, the dose per fraction to the elective regions and to the gross tumor typically ranges from 1.6 to 2.2 Gy [18].…”

Comparison of outcomes between overlapping structure-based and non-overlapping structure-based optimization for simultaneous integrated boost IMRT for malignant gliomas

“…Mohan et al 17 reported that the dose distributions provided by SIB-IMRT for head and neck cancers were more conformal than those with sequential-IMRT, and the doses to normal tissues were lower than those with sequential-IMRT. Dogan et al 18 reported that SIB-IMRT for head and neck, lung, and prostate cancers could markedly reduce the doses to critical structures compared with sequential-IMRT. In malignant glioma, Thilmann et al 19 demonstrated that SIB-IMRT had some advantage over 3D conformal radiotherapy with regard to homogeneity of the CTV-A and reduction of the dose to the normal brain.…”